中国处方药
中國處方藥
중국처방약
CHINA PRESCRIPTION DRUG
2014年
9期
13-14,15
,共3页
多囊卵巢综合征%GnRH拮抗剂%GnRH激动剂
多囊卵巢綜閤徵%GnRH拮抗劑%GnRH激動劑
다낭란소종합정%GnRH길항제%GnRH격동제
Polycystic ovary syndrome%GnRH antagonist%GnRH agonists
目的:研究不同促排卵方案治疗多囊卵巢综合征的临床效果。方法选取120例多囊卵巢综合征患者,随机分为两组,各60例,对照组给予GnRH激动剂长方案治疗,观察组给予GnRH拮抗剂治疗,对比两组患者临床疗效。结果观察组患者Gn剂量、HCG日LH水平、E2水平以及周期取消率明显低于对照组,差异有统计学意义(P<0.05);观察组在获卵数、MII卵泡数、临床妊娠率、胚胎种植率、流产率及OHSS发生率等情况与对照组相比差异无统计学意义(P>0.05)。结论采用GnRH-A方案进行促排卵治疗多囊卵巢综合征疗效显著,有效减少Gn用量,降低周期取消率及OHSS发生率。
目的:研究不同促排卵方案治療多囊卵巢綜閤徵的臨床效果。方法選取120例多囊卵巢綜閤徵患者,隨機分為兩組,各60例,對照組給予GnRH激動劑長方案治療,觀察組給予GnRH拮抗劑治療,對比兩組患者臨床療效。結果觀察組患者Gn劑量、HCG日LH水平、E2水平以及週期取消率明顯低于對照組,差異有統計學意義(P<0.05);觀察組在穫卵數、MII卵泡數、臨床妊娠率、胚胎種植率、流產率及OHSS髮生率等情況與對照組相比差異無統計學意義(P>0.05)。結論採用GnRH-A方案進行促排卵治療多囊卵巢綜閤徵療效顯著,有效減少Gn用量,降低週期取消率及OHSS髮生率。
목적:연구불동촉배란방안치료다낭란소종합정적림상효과。방법선취120례다낭란소종합정환자,수궤분위량조,각60례,대조조급여GnRH격동제장방안치료,관찰조급여GnRH길항제치료,대비량조환자림상료효。결과관찰조환자Gn제량、HCG일LH수평、E2수평이급주기취소솔명현저우대조조,차이유통계학의의(P<0.05);관찰조재획란수、MII란포수、림상임신솔、배태충식솔、유산솔급OHSS발생솔등정황여대조조상비차이무통계학의의(P>0.05)。결론채용GnRH-A방안진행촉배란치료다낭란소종합정료효현저,유효감소Gn용량,강저주기취소솔급OHSS발생솔。
Objective To study the clinical effect of different methods of promoting ovulation in patients with polycystic ovarian syndrome.Methods 120 cases of polycystic ovary syndrome patients were randomly divided into two groups, each of 60 cases. The control group was given GnRH agonist treatment, the observation group was given GnRH antagonist treatment, the clinical efficacy were compared between two groups.Results In the observation group, Gn, HCG, LH, dose level and E2 level cycle cancellation rate was significantly lower than that of the control group, the difference was significant(P<0.05); in the observation group, the number of oocytes, the number of follicles in MII, clinical pregnancy rate, implantation rate, abortion rate and OHSS rate were compared with the control group no significant difference significance(P>0.05).Conclusion The GnRH-A scheme is the promoting effect of ovulation in polycystic ovary syndrome significantly, effectively reduce the amount of Gn, reduce the incidence rate of OHSS and cycle cancellation, is worth the clinical promotion.